@article{slamonPhaseIIIRandomized2018,
  title = {Phase {{III Randomized Study}} of {{Ribociclib}} and {{Fulvestrant}} in {{Hormone Receptor-Positive}}, {{Human Epidermal Growth Factor Receptor}} 2-{{Negative Advanced Breast Cancer}}: {{MONALEESA-3}}},
  shorttitle = {Phase {{III Randomized Study}} of {{Ribociclib}} and {{Fulvestrant}} in {{Hormone Receptor-Positive}}, {{Human Epidermal Growth Factor Receptor}} 2-{{Negative Advanced Breast Cancer}}},
  author = {Slamon, Dennis J. and Neven, Patrick and Chia, Stephen and Fasching, Peter A. and De Laurentiis, Michelino and Im, Seock-Ah and Petrakova, Katarina and Bianchi, Giulia Val and Esteva, Francisco J. and Mart{\'i}n, Miguel and Nusch, Arnd and Sonke, Gabe S. and {De la Cruz-Merino}, Luis and Beck, J. Thaddeus and Pivot, Xavier and Vidam, Gena and Wang, Yingbo and Rodriguez Lorenc, Karen and Miller, Michelle and Taran, Tetiana and Jerusalem, Guy},
  year = {2018},
  month = aug,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {36},
  number = {24},
  pages = {2465--2472},
  issn = {1527-7755},
  doi = {10.1200/JCO.2018.78.9909},
  langid = {english},
  pmid = {29860922},
  keywords = {\_tablet,notion}
}


@article{austinUsePropensityScore2014,
  title = {The Use of Propensity Score Methods with Survival or Time-to-Event Outcomes: Reporting Measures of Effect Similar to Those Used in Randomized Experiments},
  shorttitle = {The Use of Propensity Score Methods with Survival or Time-to-Event Outcomes},
  author = {Austin, Peter C},
  date = {2014-03-30},
  year={2014},
  journal = {Statistics in Medicine},
  shortjournal = {Stat Med},
  volume = {33},
  number = {7},
  eprint = {24122911},
  eprinttype = {pmid},
  pages = {1242--1258},
  issn = {0277-6715},
  doi = {10.1002/sim.5984},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285179/},
  urldate = {2023-09-20},
  pmcid = {PMC4285179}
}

@article{austinIntroductionPropensityScore2011,
  title = {An {{Introduction}} to {{Propensity Score Methods}} for {{Reducing}} the {{Effects}} of {{Confounding}} in {{Observational Studies}}},
  author = {Austin, Peter C.},
  date = {2011-05},
  journaltitle = {Multivariate Behavioral Research},
  shortjournal = {Multivariate Behav Res},
  volume = {46},
  number = {3},
  eprint = {21818162},
  eprinttype = {pmid},
  pages = {399--424},
  issn = {0027-3171},
  doi = {10.1080/00273171.2011.568786},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144483/},
  urldate = {2023-09-20},
  pmcid = {PMC3144483}
}

@article{tripathyRibociclibEndocrineTherapy2018,
  title = {Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor-Positive, Advanced Breast Cancer ({{MONALEESA-7}}): A Randomised Phase 3 Trial},
  shorttitle = {Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor-Positive, Advanced Breast Cancer ({{MONALEESA-7}})},
  author = {Tripathy, Debu and Im, Seock-Ah and Colleoni, Marco and Franke, Fabio and Bardia, Aditya and Harbeck, Nadia and Hurvitz, Sara A. and Chow, Louis and Sohn, Joohyuk and Lee, Keun Seok and {Campos-Gomez}, Saul and Villanueva Vazquez, Rafael and Jung, Kyung Hae and Babu, K. Govind and {Wheatley-Price}, Paul and De Laurentiis, Michelino and Im, Young-Hyuck and Kuemmel, Sherko and {El-Saghir}, Nagi and Liu, Mei-Ching and Carlson, Gary and Hughes, Gareth and {Diaz-Padilla}, Ivan and Germa, Caroline and Hirawat, Samit and Lu, Yen-Shen},
  year = {2018},
  month = jul,
  journal = {The Lancet. Oncology},
  volume = {19},
  number = {7},
  pages = {904--915},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(18)30292-4},
  langid = {english},
  pmid = {29804902},
  keywords = {\_tablet,notion}
}
@article{hortobagyiUpdatedResultsMONALEESA22018,
  title = {Updated Results from {{MONALEESA-2}}, a Phase {{III}} Trial of First-Line Ribociclib plus Letrozole versus Placebo plus Letrozole in Hormone Receptor-Positive, {{HER2-negative}} Advanced Breast Cancer},
  author = {Hortobagyi, G. and Stemmer, S. and Burris, H. and Yap, Y. and Sonke, G. and {Paluch-Shimon}, S. and Campone, M. and Petr{\'a}kov{\'a}, K. and Blackwell, K. and Winer, E. and Janni, W. and Verma, S. and Conte, P. and Arteaga, C. and Cameron, D. and Mondal, S. and Su, F. and Miller, M. and Elmeliegy, M. and Germa, C. and O'Shaughnessy, J.},
  year = {2018},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1093/annonc/mdy155},
  keywords = {\_tablet,notion},
  annotation = {243 citations (Crossref) [2021-11-15]}
}



@article{finnCyclindependentKinaseInhibitor2015a,
  title = {The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Letrozole versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, {{HER2-negative}}, Advanced Breast Cancer ({{PALOMA-1}}/{{TRIO-18}}): A Randomised Phase 2 Study},
  shorttitle = {The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Letrozole versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, {{HER2-negative}}, Advanced Breast Cancer ({{PALOMA-1}}/{{TRIO-18}})},
  author = {Finn, Richard S and Crown, John P and Lang, Istvan and Boer, Katalin and Bondarenko, Igor M and Kulyk, Sergey O and Ettl, Johannes and Patel, Ravindranath and Pinter, Tamas and Schmidt, Marcus and Shparyk, Yaroslav and Thummala, Anu R and Voytko, Nataliya L and Fowst, Camilla and Huang, Xin and Kim, Sindy T and Randolph, Sophia and Slamon, Dennis J},
  year = {2015},
  month = jan,
  journal = {The Lancet Oncology},
  volume = {16},
  number = {1},
  pages = {25--35},
  issn = {14702045},
  doi = {10.1016/S1470-2045(14)71159-3},
  urldate = {2022-03-03},
  abstract = {Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and synergy with anti-oestrogens. We aimed to assess the safety and efficacy of palbociclib in combination with letrozole as firstline treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer.},
  langid = {english},
  note = {\url{https://linkinghub.elsevier.com/retrieve/pii/S1470204514711593}}
}

@article{rugoImpactPalbociclibLetrozole2018,
  title = {Impact of Palbociclib plus Letrozole on Patient-Reported Health-Related Quality of Life: Results from the {{PALOMA-2}} Trial},
  shorttitle = {Impact of Palbociclib plus Letrozole on Patient-Reported Health-Related Quality of Life},
  author = {Rugo, H. S. and Di{\'e}ras, V. and Gelmon, K. A. and Finn, R. S. and Slamon, D. J. and Martin, M. and Neven, P. and Shparyk, Y. and Mori, A. and Lu, D. R. and Bhattacharyya, H. and Bartlett, C. H. U. a. N. G. and Iyer, S. and Johnston, S. and Ettl, J. and Harbeck, N.},
  year = {2018},
  month = apr,
  journal = {Annals of Oncology: Official Journal of the European Society for Medical Oncology},
  volume = {29},
  number = {4},
  pages = {888--894},
  issn = {1569-8041},
  doi = {10.1093/annonc/mdy012},
  langid = {english},
  pmcid = {PMC5913649},
  pmid = {29360932},
  keywords = {\_tablet,notion}
}
@article{vermaPalbociclibCombinationFulvestrant2016,
  title = {Palbociclib in {{Combination With Fulvestrant}} in {{Women With Hormone Receptor-Positive}}/{{HER2-Negative Advanced Metastatic Breast Cancer}}: {{Detailed Safety Analysis From}} a {{Multicenter}}, {{Randomized}}, {{Placebo-Controlled}}, {{Phase III Study}} ({{PALOMA-3}})},
  shorttitle = {Palbociclib in {{Combination With Fulvestrant}} in {{Women With Hormone Receptor-Positive}}/{{HER2-Negative Advanced Metastatic Breast Cancer}}},
  author = {Verma, Sunil and Bartlett, Cynthia Huang and Schnell, Patrick and DeMichele, Angela M. and Loi, Sherene and Ro, Jungsil and Colleoni, Marco and Iwata, Hiroji and Harbeck, Nadia and Cristofanilli, Massimo and Zhang, Ke and Thiele, Alexandra and Turner, Nicholas C. and Rugo, Hope S.},
  year = {2016},
  month = oct,
  journal = {The Oncologist},
  volume = {21},
  number = {10},
  pages = {1165--1175},
  issn = {1549-490X},
  doi = {10.1634/theoncologist.2016-0097},
  langid = {english},
  pmcid = {PMC5061543},
  pmid = {27368881},
  keywords = {\_tablet,notion}
}
@article{sledgeMONARCHAbemaciclibCombination2017,
  title = {{{MONARCH}} 2: {{Abemaciclib}} in {{Combination With Fulvestrant}} in {{Women With HR}}+/{{HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy}}},
  shorttitle = {{{MONARCH}} 2},
  author = {Sledge, George W. and Toi, Masakazu and Neven, Patrick and Sohn, Joohyuk and Inoue, Kenichi and Pivot, Xavier and Burdaeva, Olga and Okera, Meena and Masuda, Norikazu and Kaufman, Peter A. and Koh, Han and Grischke, Eva-Maria and Frenzel, Martin and Lin, Yong and Barriga, Susana and Smith, Ian C. and Bourayou, Nawel and {Llombart-Cussac}, Antonio},
  year = {2017},
  month = sep,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {35},
  number = {25},
  pages = {2875--2884},
  issn = {1527-7755},
  doi = {10.1200/JCO.2017.73.7585},
  langid = {english},
  pmid = {28580882}
}
@article{goetzMONARCHAbemaciclibInitial2017,
  title = {{{MONARCH}} 3: {{Abemaciclib As Initial Therapy}} for {{Advanced Breast Cancer}}},
  shorttitle = {{{MONARCH}} 3},
  author = {Goetz, Matthew P. and Toi, Masakazu and Campone, Mario and Sohn, Joohyuk and {Paluch-Shimon}, Shani and Huober, Jens and Park, In Hae and Tr{\'e}dan, Olivier and Chen, Shin-Cheh and Manso, Luis and Freedman, Orit C. and Garnica Jaliffe, Georgina and Forrester, Tammy and Frenzel, Martin and Barriga, Susana and Smith, Ian C. and Bourayou, Nawel and Di Leo, Angelo},
  year = {2017},
  month = nov,
  journal = {Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
  volume = {35},
  number = {32},
  pages = {3638--3646},
  issn = {1527-7755},
  doi = {10.1200/JCO.2017.75.6155},
  langid = {english},
  pmid = {28968163}
}
@article{cristofanilliFulvestrantPalbociclibFulvestrant2016a,
  title = {Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, {{HER2-negative}} Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy ({{PALOMA-3}}): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial},
  shorttitle = {Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, {{HER2-negative}} Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy ({{PALOMA-3}})},
  author = {Cristofanilli, Massimo and Turner, Nicholas C. and Bondarenko, Igor and Ro, Jungsil and Im, Seock-Ah and Masuda, Norikazu and Colleoni, Marco and DeMichele, Angela and Loi, Sherene and Verma, Sunil and Iwata, Hiroji and Harbeck, Nadia and Zhang, Ke and Theall, Kathy Puyana and Jiang, Yuqiu and Bartlett, Cynthia Huang and Koehler, Maria and Slamon, Dennis},
  date = {2016-04},
  journaltitle = {The Lancet. Oncology},
  shortjournal = {Lancet Oncol},
  volume = {17},
  number = {4},
  eprint = {26947331},
  eprinttype = {pmid},
  pages = {425--439},
  issn = {1474-5488},
  doi = {10.1016/S1470-2045(15)00613-0},
  langid = {english}
}
@article{harbeckCDK4InhibitorsHR2021,
  title = {{{CDK4}}/6 Inhibitors in {{HR}}+/{{HER2-}} Advanced/Metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies},
  shorttitle = {{{CDK4}}/6 Inhibitors in {{HR}}+/{{HER2-}} Advanced/Metastatic Breast Cancer},
  author = {Harbeck, Nadia and Bartlett, Meaghan and Spurden, Dean and Hooper, Becky and Zhan, Lin and Rosta, Emily and Cameron, Chris and Mitra, Debanjali and Zhou, Anna},
  date = {2021-06},
  journaltitle = {Future Oncology},
  volume = {17},
  number = {16},
  pages = {2107--2122},
  publisher = {{Future Medicine}},
  issn = {1479-6694},
  doi = {10.2217/fon-2020-1264},
  url = {https://www.futuremedicine.com/doi/full/10.2217/fon-2020-1264},
  urldate = {2023-07-19},
  keywords = {biological therapy,breast,CDK4/6i,metastasis,real-world evidence,systematic literature review}
}
